A U.S. Patent Office tribunal has ruled against Nobel Prize-winning scientists Jennifer Doudna and Emmanuelle Charpentier for ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office ...

As reported by Reuters, the Patent Trial and Appeal Board found that Broad scientists had conceived the practical eukaryotic ...

In back-to-back studies published in Nature, researchers from Purdue University and Columbia University report a naturally ...

Researchers have built a series of CRISPR-based platforms that can switch endogenous genes on and, just as critically, dial ...

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the ...

CRISPR is a powerful DNA-editing tool that has underpinned huge advancements in human health care in the last decade. It is a ...

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

Researchers revealed a CRISPR system that activates gene expression rather than cutting DNA, using RNA-guided targeting. The ...

Biotech start-up CRISPR Therapeutics made the announcement this morning. That is, it intends to sell $350 million worth of ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

One stock that's been on my watch list for a while is CRISPR Therapeutics (NASDAQ: CRSP). The company has an intriguing ...